{"id":"W4230932386","doi":"10.2165/00128413-200715990-00047","title":"Health Canada has granted expanded approval of lumiracoxib [Prexige; Novartis] for the treatment of acute and chronic osteoarthritis","year":2007,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"","keywords":"Medicine; Osteoarthritis; Pharmacy; Alternative medicine; Physical therapy; Intensive care medicine; Family medicine","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001339671,0.000489609,0.000723569,0.001290754,0.001730499,0.001383569,0.0009557947,0.002517665,0.03055227],"category_scores_gemma":[0.002552752,0.0003026986,0.0009370495,0.0007851869,0.001038359,0.0002908627,0.0006834805,0.002859531,0.004255975],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.006766068,"about_ca_system_score_gemma":0.03423879,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.3019677,"about_ca_topic_score_gemma":0.6485081,"domain_scores_codex":[0.9984584,0.000192586,0.0000469649,0.00008849967,0.0008248003,0.000388714],"domain_scores_gemma":[0.9956051,0.0005430181,0.0001926444,0.00008843042,0.002168035,0.00140276],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00333797,0.0008538603,0.009369525,0.000717539,0.0001829446,0.00251668,0.0001308849,0.0004116694,0.02256414,0.005807365,0.6161721,0.3379353],"study_design_scores_gemma":[0.001403967,0.001180165,0.02976317,0.0002011317,0.0001472501,0.001728706,0.00009600112,0.0005902171,0.003874441,0.0003372035,0.9606269,0.0000509516],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"other","genre_gemma":"other","genre_scores_codex":[0.09301571,0.08717605,0.00439287,0.132536,0.01835709,0.001905754,0.01252851,0.001931215,0.6481568],"genre_scores_gemma":[0.3391515,0.02915508,0.01054247,0.05439904,0.005446843,0.0002650539,0.0142796,0.0002597102,0.5465007],"genre_candidate":"other","genre_consensus":"other","teacher_disagreement_score":0.6980323,"threshold_uncertainty_score":0.6004201,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01777054040401422,"score_gpt":0.2917364214198742,"score_spread":0.2739658810158599,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}